GRACE in partnership with LUNGevity Foundation are thrilled to offer our next webinar on Wednesday, October 24th, at 6:30 PM Eastern/3:30 PM Pacific...
A manuscript by Pérol and colleagues just being published in the Journal of Clinical Oncology describes a trial I’ve found intriguing but inexplicably...
Just last week I reviewed the favorable results in a randomized phase II clinical trial with the novel vascular-targeting immunotherapy bavituximab...
The last topic covered by Dr. Neal was on exciting work on molecular targets for squamous NSCLC. Long the poor stepchild to adenocarcinoma and other...
Here is Dr. Neal's summary from the ASCO 2012 Lung Cancer Highlights program of the SELECT Trial, which he led and presented, of adjuvant (post...
Dr. Sarah Goldberg from Yale Cancer Center describes the methods she uses to obtain tissue samples for molecular testing.
[powerpress]
Dr. Lecia Sequist of Massachusetts General Hospital offers her insights on how to approach a patient with gradual progression in a single site, especially in the brain, or more multifocal progression after a good initial response to a targeted agent for lung cancer.
[powerpress]
Dr. Rosalyn Juergens, McMaster University, offers her view on the best way to approach the common scenario of an EGFR mutation or other "driver mutation" being identified after a patient is already on first line chemotherapy. When should we switch from one treatment to another?
[powerpress]
Dr. Ravi Salgia from University of Chicago describes which patients with advanced NSCLC he seeks molecular marker testing on, and the particular markers he prioritizes.
[powerpress]
Dr. Geoffrey Oxnard, Dana Farber Cancer Institute, discusses the issue of patients or payers objecting to repeat biopsies.
[powerpress]
Dr. Greg Riely, from Memorial Sloan-Kettering, discusses the concept of multiplex next generation sequencing and how it could change molecular oncology.
[powerpress]
Dr. Phil Bonomi, from Rush University, provides his view on the targeted therapy approaches most likely to become clinically useful in lung cancer over the next several years.
[powerpress]
Dr. Karen Kelly of the University of California, Davis, discusses the evidence and her personal interpretation and recommended approach to maintenance therapy for advanced non-small cell lung cancer.
[powerpress]
Dr. David Spigel addresses the question of whether to obtain molecular marker results in patients with early stage lung cancer and what to do with that information if it is available for potential application in the adjuvant setting.
[powerpress]
Welcome to the new CancerGRACE.org! Explore our fresh look and improved features—take a quick tour to see what’s new.